GDC 7035
Alternative Names: GDC-7035; RG-6620Latest Information Update: 24 Feb 2025
At a glance
- Originator Genentech
- Class Antineoplastics
- Mechanism of Action KRAS protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 14 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Australia (unspecified route) (NCT06619587)
- 14 Nov 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease) in Australia (unspecified route) (NCT06619587)
- 07 Oct 2024 Preclinical trials in Solid tumours in USA (unspecified route) prior October 2024 (Genentech pipeline, October 2024)